Advanced search
Publication Cover
International Journal of Chronic Obstructive Pulmonary Disease Volume 11, 2016 - Issue
Submit an article Journal homepage
48
Views
13
CrossRef citations to date
0
Altmetric
Original Research

Indacaterol/glycopyrronium in symptomatic patients with COPD (GOLD B and GOLD D) versus salmeterol/fluticasone: ILLUMINATE/LANTERN pooled analysis

Claus Vogelmeier1 Department of Medicine, Pulmonary and Critical Care Medicine, University Medical Center Giessen and Marburg, Philipps-University Marburg, Member of the German Center for Lung Research (DZL), Marburg, GermanyCorrespondence[email protected]
,
Nanshan Zhong2 State Key Laboratory, Guangzhou Institute of Respiratory Diseases, First Affiliated Hospital, Guangzhou Medical University, Guangzhou
,
Michael J Humphries3 Beijing Novartis Pharma Co. Ltd., Shanghai, People’s Republic of China
,
Karen Mezzi4 Novartis Pharma AG, Basel, Switzerland
,
Robert Fogel5 Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA
,
Giovanni Bader4 Novartis Pharma AG, Basel, Switzerland
,
Francesco Patalano4 Novartis Pharma AG, Basel, Switzerland
&
Donald Banerji5 Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA
 show all
Pages 3189-3197 | Published online: 14 Dec 2016

Citations (13)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (4)

Paola Rogliani, Luigino Calzetta, Maria Gabriella Matera, Nicola di Daniele, Andrea Girolami, Mario Cazzola & Josuel Ora. (2019) Inhaled therapies and cardiovascular risk in patients with chronic obstructive pulmonary disease. Expert Opinion on Pharmacotherapy 20:6, pages 737-750.
Read now
Paola Rogliani, Josuel Ora, Maria Gabriella Matera, Mario Cazzola & Luigino Calzetta. (2018) The safety of dual bronchodilation on cardiovascular serious adverse events in COPD. Expert Opinion on Drug Safety 17:6, pages 589-596.
Read now
Maria Gabriella Matera, Luigino Calzetta, Ermanno Puxeddu, Paola Rogliani & Mario Cazzola. (2018) A safety comparison of LABA+LAMA vs LABA+ICS combination therapy for COPD. Expert Opinion on Drug Safety 17:5, pages 509-517.
Read now
Donald P Tashkin & Nicholas J Gross. (2018) Inhaled glycopyrrolate for the treatment of chronic obstructive pulmonary disease. International Journal of Chronic Obstructive Pulmonary Disease 13, pages 1873-1888.
Read now

Articles from other publishers (9)

A.L. Aguilar-Shea & C. Gallardo-Mayo. (2022) Revisión narrativa de la terapia inhalatoria en la EPOC. Medicina de Familia. SEMERGEN 48:3, pages 214-218.
Crossref
Tanja Fens, Simon van der Pol, Janwillem W.H. Kocks, Maarten J. Postma & Job F.M. van Boven. (2019) Economic Impact of Reducing Inappropriate Inhaled Corticosteroids Use in Patients With Chronic Obstructive Pulmonary Disease: ISPOR's Guidance on Budget Impact in Practice. Value in Health 22:10, pages 1092-1101.
Crossref
Salvatore Fuschillo, Antonio Molino, Cristiana Stellato, Andrea Motta & Mauro Maniscalco. (2019) Blood eosinophils as biomarkers of therapeutic response to chronic obstructive pulmonary disease: Still work in progress. European Journal of Internal Medicine 68, pages 1-5.
Crossref
Eneida M. Harrison & Victor Kim. (2019) Long-acting maintenance pharmacotherapy in chronic obstructive pulmonary disease. Respiratory Medicine: X 1, pages 100009.
Crossref
Javier Milara, Lucía Díaz-Platas, Sonia Contreras, Pilar Ribera, Inés Roger, Beatriz Ballester, Paula Montero, Ángel Cogolludo, Esteban Morcillo & Julio Cortijo. (2018) MUC1 deficiency mediates corticosteroid resistance in chronic obstructive pulmonary disease. Respiratory Research 19:1.
Crossref
Fabiano Di Marco, Giovanni Sotgiu, Pierachille Santus, Denis E. O’Donnell, Kai-Michael Beeh, Simone Dore, Maria Adelaide Roggi, Lisa Giuliani, Francesco Blasi & Stefano Centanni. (2018) Long-acting bronchodilators improve exercise capacity in COPD patients: a systematic review and meta-analysis. Respiratory Research 19:1.
Crossref
James D. Chalmers. (2018) POINT: Should an Attempt Be Made to Withdraw Inhaled Corticosteroids in All Patients With Stable GOLD 3 (30% ≤ FEV1 < 50% Predicted) COPD? Yes. Chest 153:4, pages 778-782.
Crossref
Marc Miravitlles, Antonio Anzueto & José R. Jardim. (2017) Optimizing bronchodilation in the prevention of COPD exacerbations. Respiratory Research 18:1.
Crossref
Joy Creaser-Thomas, Vignesh Rajasundaram & Gwyneth A Davies. 2017. A Worldwide Yearly Survey of New Data in Adverse Drug Reactions. A Worldwide Yearly Survey of New Data in Adverse Drug Reactions 161 171 .

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.